SE0201635D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0201635D0
SE0201635D0 SE0201635A SE0201635A SE0201635D0 SE 0201635 D0 SE0201635 D0 SE 0201635D0 SE 0201635 A SE0201635 A SE 0201635A SE 0201635 A SE0201635 A SE 0201635A SE 0201635 D0 SE0201635 D0 SE 0201635D0
Authority
SE
Sweden
Prior art keywords
novel compounds
useful
formula
relates
present
Prior art date
Application number
SE0201635A
Other languages
English (en)
Inventor
Simon Teague
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201635A priority Critical patent/SE0201635D0/sv
Publication of SE0201635D0 publication Critical patent/SE0201635D0/sv
Priority to TW092114174A priority patent/TW200407305A/zh
Priority to CA002487675A priority patent/CA2487675A1/en
Priority to PCT/SE2003/000856 priority patent/WO2003101961A1/en
Priority to ES03725970T priority patent/ES2360936T3/es
Priority to US10/516,557 priority patent/US7166607B2/en
Priority to BR0311494-5A priority patent/BR0311494A/pt
Priority to AU2003228201A priority patent/AU2003228201A1/en
Priority to PL03375111A priority patent/PL375111A1/xx
Priority to RU2004135064/04A priority patent/RU2288914C2/ru
Priority to KR10-2004-7019452A priority patent/KR20050010507A/ko
Priority to AT03725970T priority patent/ATE501118T1/de
Priority to DE60336314T priority patent/DE60336314D1/de
Priority to MXPA04011876A priority patent/MXPA04011876A/es
Priority to CNB038183447A priority patent/CN100404505C/zh
Priority to EP03725970A priority patent/EP1513812B1/en
Priority to UA20041109794A priority patent/UA79464C2/uk
Priority to NZ536883A priority patent/NZ536883A/en
Priority to JP2004509654A priority patent/JP4485354B2/ja
Priority to MYPI20031973A priority patent/MY133624A/en
Priority to ARP030101932A priority patent/AR039934A1/es
Priority to CO04120052A priority patent/CO5631431A2/es
Priority to ZA200409641A priority patent/ZA200409641B/xx
Priority to IS7607A priority patent/IS7607A/is
Priority to NO20045589A priority patent/NO20045589L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
SE0201635A 2002-05-30 2002-05-30 Novel compounds SE0201635D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds
TW092114174A TW200407305A (en) 2002-05-30 2003-05-26 Novel compounds
JP2004509654A JP4485354B2 (ja) 2002-05-30 2003-05-27 新規な置換インドール類
KR10-2004-7019452A KR20050010507A (ko) 2002-05-30 2003-05-27 신규 치환 인돌
MXPA04011876A MXPA04011876A (es) 2002-05-30 2003-05-27 Nuevos indoles sustituidos.
ES03725970T ES2360936T3 (es) 2002-05-30 2003-05-27 Indoles sustituidos.
US10/516,557 US7166607B2 (en) 2002-05-30 2003-05-27 Substituted indoles
BR0311494-5A BR0311494A (pt) 2002-05-30 2003-05-27 Novos indóis substituìdos
AU2003228201A AU2003228201A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
PL03375111A PL375111A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
RU2004135064/04A RU2288914C2 (ru) 2002-05-30 2003-05-27 Новые замещенные индолы
CA002487675A CA2487675A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
AT03725970T ATE501118T1 (de) 2002-05-30 2003-05-27 Substituierte indole
DE60336314T DE60336314D1 (de) 2002-05-30 2003-05-27 Substituierte indole
PCT/SE2003/000856 WO2003101961A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles
CNB038183447A CN100404505C (zh) 2002-05-30 2003-05-27 新的取代吲哚
EP03725970A EP1513812B1 (en) 2002-05-30 2003-05-27 Substituted indoles
UA20041109794A UA79464C2 (en) 2002-05-30 2003-05-27 Substituted indoles, methods for their production and method for treating disorders mediated by prostaglandin d2
NZ536883A NZ536883A (en) 2002-05-30 2003-05-27 Novel substituted indoles
MYPI20031973A MY133624A (en) 2002-05-30 2003-05-28 Thio-substituted indole acetic acid derivatives for the treatment of respiratory disease
ARP030101932A AR039934A1 (es) 2002-05-30 2003-05-30 Indoles sustituidos para el tratamiento de desordenes respiratorios
CO04120052A CO5631431A2 (es) 2002-05-30 2004-11-29 Indoles sustituidos novedosos
ZA200409641A ZA200409641B (en) 2002-05-30 2004-11-29 Novel substituted indoles.
IS7607A IS7607A (is) 2002-05-30 2004-12-21 Ný útskipt indól
NO20045589A NO20045589L (no) 2002-05-30 2004-12-22 Nye forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds

Publications (1)

Publication Number Publication Date
SE0201635D0 true SE0201635D0 (sv) 2002-05-30

Family

ID=20288018

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds

Country Status (25)

Country Link
US (1) US7166607B2 (sv)
EP (1) EP1513812B1 (sv)
JP (1) JP4485354B2 (sv)
KR (1) KR20050010507A (sv)
CN (1) CN100404505C (sv)
AR (1) AR039934A1 (sv)
AT (1) ATE501118T1 (sv)
AU (1) AU2003228201A1 (sv)
BR (1) BR0311494A (sv)
CA (1) CA2487675A1 (sv)
CO (1) CO5631431A2 (sv)
DE (1) DE60336314D1 (sv)
ES (1) ES2360936T3 (sv)
IS (1) IS7607A (sv)
MX (1) MXPA04011876A (sv)
MY (1) MY133624A (sv)
NO (1) NO20045589L (sv)
NZ (1) NZ536883A (sv)
PL (1) PL375111A1 (sv)
RU (1) RU2288914C2 (sv)
SE (1) SE0201635D0 (sv)
TW (1) TW200407305A (sv)
UA (1) UA79464C2 (sv)
WO (1) WO2003101961A1 (sv)
ZA (1) ZA200409641B (sv)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
KR20050111314A (ko) 2002-12-20 2005-11-24 암젠 인코포레이션 천식 및 알레르기성 염증 조절제들
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
JP2007508363A (ja) * 2003-10-14 2007-04-05 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DE602005006539D1 (de) 2004-03-11 2008-06-19 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivate
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
AU2005247110B2 (en) 2004-05-29 2010-08-26 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
US8273740B2 (en) * 2004-08-26 2012-09-25 Actelion Pharmaceuticals, Ltd. 2-sulfanyl-benzoimidazol-1-yi-acetic acid derivatives as CRTH2 antagonists
CA2581338A1 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
ES2314739T3 (es) * 2004-10-27 2009-03-16 Janssen Pharmaceutica Nv Derivados de indol como moduladores de receptores de progesterona.
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
NZ556657A (en) 2004-12-27 2010-10-29 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するアザインドール酸誘導体
JP5072594B2 (ja) * 2005-07-22 2012-11-14 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するインドール誘導体
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
SI2037967T1 (sl) 2006-06-16 2017-04-26 The Trustees Of The University Of Pennsylvania Antagonisti receptorja za prostaglandin d2 za zdravljenje androgene alopecije
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
EP2316824A1 (en) 2006-08-07 2011-05-04 Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates
BRPI0721477A2 (pt) * 2007-03-21 2013-01-15 Argenta Discovery Ltd derivados de Ácido indolizina acÉtico como antagonistas de crth2
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
EP2229358B1 (en) 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
ES2471919T3 (es) 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
TW201130810A (en) 2009-12-23 2011-09-16 Ironwood Pharmaceuticals Inc CRTH2 modulators
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN102791689B (zh) 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-(杂芳基-氨基)-1,2,3,4-四氢-9h-咔唑衍生物及其作为***素d2受体调节剂的用途
CN107021951B (zh) 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
AU2011326241B2 (en) 2010-11-09 2016-11-17 Ironwood Pharmaceuticals, Inc. sGC stimulators
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 7−(ヘテロアリ−ル−アミノ)−6,7,8,9−テトラヒドロピリド[1,2−a]インド−ル酢酸誘導体及びプロスタグランジンD2受容体調節剤としてのそれらの使用
WO2012158435A1 (en) * 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition
BR112014014558A8 (pt) 2011-12-16 2017-07-04 Atopix Therapeutics Ltd composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
TWI519515B (zh) 2011-12-21 2016-02-01 諾維拉治療公司 B型肝炎抗病毒劑
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
CN108938441A (zh) 2012-03-21 2018-12-07 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
EA027280B1 (ru) 2012-08-28 2017-07-31 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA026957B1 (ru) * 2012-08-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
RS63108B1 (sr) 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulatori
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (sv) 2013-07-25 2018-07-21
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN106304835A (zh) 2013-12-11 2017-01-04 铁木医药有限公司 sGC刺激剂
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (ru) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Комбинированная терапия для лечения инфекций вгв
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
MX368179B (es) 2014-03-17 2019-09-23 Idorsia Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
EP3119780B1 (en) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
JP6624616B2 (ja) 2014-09-17 2019-12-25 サイクレリオン・セラピューティクス,インコーポレーテッド sGC刺激剤
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108472510A (zh) 2015-07-30 2018-08-31 宾夕法尼亚大学理事会 用于检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
EA035752B1 (ru) 2015-09-15 2020-08-05 Идорсиа Фармасьютиклз Лтд КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-2-(8-((5-ХЛОРПИРИМИДИН-2-ИЛ)(МЕТИЛ)-АМИНО)-2-ФТОР-6,7,8,9-ТЕТРАГИДРО-5Н-ПИРИДО[3,2-b]ИНДОЛ-5-ИЛ)УКСУСНОЙ КИСЛОТЫ И СОДЕРЖАЩИЕ ЕЁ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
JP2019524710A (ja) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Sgc刺激剤の固体形態
CA3029374A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送***及相关方法
CN114835677A (zh) * 2021-02-02 2022-08-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN115093360B (zh) * 2022-07-06 2023-11-17 都创(上海)医药科技股份有限公司 一种吲哚类衍生物的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPS5239671A (en) * 1975-09-22 1977-03-28 Sankyo Co Ltd Process for preparing indole-3-thioether compounds
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) * 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
WO1994016687A1 (en) 1993-01-28 1994-08-04 The Trustees Of The University Of Pennsylvania Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
HUT74614A (en) * 1993-02-24 1997-01-28 Merck & Co Inc Nindol derivates suitable for treatment of infection by hiv and pharmaceutical compositions containing them
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AR017256A1 (es) 1997-08-21 2001-09-05 American Home Prod Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
ES2198033T3 (es) 1997-12-19 2004-01-16 Eli Lilly And Company Compuestos de imidazolina hipoglucemicos.
AU5886500A (en) 1999-06-23 2001-01-09 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (fr) 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif
CN1615873A (zh) 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 氮杂吲哚类化合物
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AU2003218962B2 (en) 2002-02-01 2008-09-25 F. Hoffmann-La Roche Ag Substituted indoles as alpha-1 agonists
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
CN1671659A (zh) 2005-09-21
CO5631431A2 (es) 2006-04-28
TW200407305A (en) 2004-05-16
ES2360936T3 (es) 2011-06-10
DE60336314D1 (de) 2011-04-21
RU2004135064A (ru) 2005-08-10
WO2003101961A1 (en) 2003-12-11
MXPA04011876A (es) 2005-03-31
NO20045589L (no) 2005-02-02
IS7607A (is) 2004-12-21
AR039934A1 (es) 2005-03-09
EP1513812B1 (en) 2011-03-09
ZA200409641B (en) 2006-02-22
PL375111A1 (en) 2005-11-28
CN100404505C (zh) 2008-07-23
UA79464C2 (en) 2007-06-25
RU2288914C2 (ru) 2006-12-10
ATE501118T1 (de) 2011-03-15
MY133624A (en) 2007-11-30
BR0311494A (pt) 2005-03-29
KR20050010507A (ko) 2005-01-27
AU2003228201A1 (en) 2003-12-19
EP1513812A1 (en) 2005-03-16
CA2487675A1 (en) 2003-12-11
JP4485354B2 (ja) 2010-06-23
US20050165055A1 (en) 2005-07-28
JP2005538955A (ja) 2005-12-22
NZ536883A (en) 2006-08-31
US7166607B2 (en) 2007-01-23

Similar Documents

Publication Publication Date Title
SE0201635D0 (sv) Novel compounds
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
SE0202241D0 (sv) Novel Compounds
TW200510301A (en) Novel compounds
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
TW200503724A (en) Novel pharmaceuticals
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
TW200720260A (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
TW200728258A (en) Novel compounds
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
GB0519760D0 (en) Novel compounds
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DK1648904T3 (da) N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander
GB0215392D0 (en) Chemical compounds
MXPA05011289A (es) Compuestos de fosfato que tienen actividad inmunomoduladora.